According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:
1. Puma Biotechnology (NASDAQ:PBYI)
The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.
Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 49, which is 26 points higher than the biotech industry average of 23.
PBYI passed 16 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock lose -12.71% over the past year, overperforming other biotech stocks by 55 percentage points.
Puma Biotechnology has an average 1 year
price target of $7.00, an upside of 121.52% from Puma Biotechnology's current stock price of $3.16.
Puma Biotechnology stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Ptc Therapeutics (NASDAQ:PTCT)
The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.
Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.
PTCT passed 11 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 54.22% over the past year, overperforming other biotech stocks by 122 percentage points.
Ptc Therapeutics has an average 1 year
price target of $69.62, an upside of 36.66% from Ptc Therapeutics's current stock price of $50.94.
Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 53.85% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.
3. Rigel Pharmaceuticals (NASDAQ:RIGL)
The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.
Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.
RIGL passed 11 out of 33 due diligence checks and has average fundamentals. Rigel Pharmaceuticals has seen its stock return 97.46% over the past year, overperforming other biotech stocks by 165 percentage points.
Rigel Pharmaceuticals has an average 1 year
price target of $39.75, an upside of 89.2% from Rigel Pharmaceuticals's current stock price of $21.01.
Rigel Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Rigel Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.